# Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

> **NCT05942573** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 107 (estimated)

## Conditions studied

- Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

## Interventions

- **DRUG:** Serplulimab+Paclitaxel+Apatinib
- **DRUG:** Paclitaxel±Ramucirumab

## Key facts

- **NCT ID:** NCT05942573
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-24
- **Primary completion:** 2023-10
- **Final completion:** 2024-12-31
- **Target enrollment:** 107 (ESTIMATED)
- **Last updated:** 2023-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05942573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05942573, "Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial". Retrieved via AI Analytics 2026-09-20 from https://api.ai-analytics.org/clinical/NCT05942573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*